IGF-1 vs PT-141 (Bremelanotide)
IGF-1 and PT-141 (Bremelanotide) are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds, while PT-141 (Bremelanotide) is cyclic heptapeptide, melanocortin receptor agonist — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (misfolding and irreversible denaturation for IGF-1, tryptophan photo-oxidation for PT-141 (Bremelanotide)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
IGF-1 — origin
IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.
PT-141 (Bremelanotide) — origin
PT-141 is a metabolite of Melanotan II, and its history is an unusually direct case of a side effect becoming the research programme. Melanotan II was developed as a synthetic α-MSH analogue for pigmentation research; an unanticipated effect observed during that work redirected attention to the metabolite, which was then developed separately as bremelanotide.
IGF-1 research themes
Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.
Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.
Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.
PT-141 (Bremelanotide) research themes
Acts at melanocortin receptors, with MC3R and MC4R the subtypes of research interest.
Distinguished in the literature by acting centrally, unlike vascular-mechanism compounds in adjacent research areas.
Its origin as a metabolite of a pigmentation-research compound is central to understanding its development history.
The lactam bridge restricts conformational freedom, a common strategy for improving receptor selectivity.
IGF-1 handling
- Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
- Use a carrier protein and low-bind labware to prevent adsorptive loss.
- Aliquot for single use; do not re-freeze reconstituted protein.
PT-141 (Bremelanotide) handling
- Protect from light at all stages.
- Standard gentle reconstitution; the constrained ring is not agitation-sensitive in the way flexible long chains are.
- Store refrigerated and aliquot rather than repeatedly sampling one vial.
Both third-party tested
Every Popular Peptides batch of IGF-1 and PT-141 (Bremelanotide) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
IGF-1 reference
Related comparisons
IGF-1 and PT-141 (Bremelanotide) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.